Living With T1D/August 31, 2026/2 min read

Advanced Insulin Pumps Show Promise in Correctional Settings

A small study found that advanced hybrid closed-loop systems—automated insulin delivery devices—improved blood sugar control for incarcerated people with Type 1 diabetes, even in highly restricted environments.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

Advanced hybrid closed-loop (aHCL) systems helped people with Type 1 diabetes in a correctional facility lower their HbA1c from 9.7% to 7.8% over three months
Time in range—the percentage of time blood sugar stayed in target—improved from 41% to 49%
The study included only six people, so findings are preliminary and would need confirmation in larger studies
No serious low blood sugar events or diabetic ketoacidosis occurred during the three-month period

Diabetes Care in Prisons Is Complex

Managing Type 1 diabetes in correctional facilities presents unique challenges. Incarcerated individuals often have limited control over their daily schedules, restricted access to diabetes technology, and fewer choices about meal timing and content. These constraints can make blood sugar management significantly harder than it is in community settings.

What the Study Found

Researchers in a correctional facility studied five adults with Type 1 diabetes who were started on advanced hybrid closed-loop (aHCL) systems—automated insulin pumps that adjust insulin delivery based on continuous glucose monitoring data. Over three months, their median HbA1c (a measure of average blood sugar over time) dropped from 9.7% to 7.8%, a statistically significant improvement.

Time in range—the percentage of time spent with blood sugar in target—improved from 41% to 49%. Time spent with high blood sugar decreased from 57.5% to 43%. No participants experienced severe low blood sugar events or diabetic ketoacidosis, a serious complication.

Important Limitations

This was a small case series involving only six people, five of whom completed the study. While the results are encouraging, a study this size cannot definitively prove that aHCL systems work well for all incarcerated people with Type 1 diabetes. The findings lasted only three months, so longer-term outcomes remain unknown.

The research suggests aHCL technology deserves further investigation in correctional settings, but larger and longer studies would be needed to confirm these initial results.

What This Means

For people with Type 1 diabetes in correctional facilities, access to advanced diabetes technology has been limited partly due to assumptions about feasibility in restrictive environments. This study provides preliminary evidence that automated insulin delivery systems can work and improve blood sugar control, even under challenging circumstances.

If confirmed in larger studies, findings like these could help expand access to life-improving diabetes technology for a vulnerable population that currently has few treatment options.

Evidence label

Source: Acta diabetologica. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.